California Startup Administers First AI-Designed Virus to a Human Patient

A California startup called Radical Numerics has administered what it claims is the first AI-designed bacteriophage — a virus engineered to target a specific bacterium — to a living human patient. The treatment used a compassionate-use pathway, meaning regulatory approval was not required, but a licensed physician oversaw the case. If the claim holds up to peer review, it marks the first time an AI-generated biological agent has been administered therapeutically in a human.

Antibiotic resistance is one of the defining medical crises of the next decade. The World Health Organization projects drug-resistant infections will cause 10 million deaths annually by 2050 if current trends continue. Bacteriophage therapy — using viruses that specifically infect and kill bacteria — is an alternative that has seen renewed interest, but traditional phage development is slow, expensive, and dependent on finding naturally occurring phages in environmental samples that happen to match the target pathogen. Radical Numerics is attempting to remove the "happen to" from that equation.

What Radical Numerics built

According to GTRT's reporting on the announcement, the company's AI model — called Omnii-1 — was trained on genomic data and phage-host interaction databases. Given a target bacterium, the model generates candidate phage sequences designed to infect and destroy that specific strain.

The patient in this case had an antibiotic-resistant bacterial infection. Standard antibiotics had failed. The treating physician requested compassionate use, which in the United States allows access to unapproved treatments when no alternatives exist and the patient or their representative consents. Radical Numerics then used Omnii-1 to generate a custom phage sequence, synthesized it, and administered it.

Key unknowns

Radical Numerics has not publicly disclosed:

• Whether the treatment was effective
• The specific pathogen targeted
• The patient's current condition
• Whether results have been submitted for peer review

The company stated that outcomes are pending peer review before public disclosure. That's a reasonable scientific standard — and it means the headline claim of "first AI-designed phage administered to a human" is established, but the headline of "AI cured an antibiotic-resistant infection" is not.

Why this moment matters regardless of the outcome

The significance isn't whether this particular patient recovered. It's what the event represents as a proof of concept:

• AI-designed biological agents can clear regulatory review for compassionate use, meaning the safety evaluation process found no obvious bars to administration.
• The speed gap is real. Traditional phage therapy requires finding or engineering a matching natural phage, a process that can take months. If AI-designed phages can be generated and synthesized faster, that speed advantage becomes clinically meaningful for patients who cannot wait.
• The liability and oversight framework hasn't caught up. Compassionate use is a narrow exception, not a regulatory pathway for scaled deployment. If Omnii-1 produces effective results, Radical Numerics will need to navigate FDA clinical trials — a process measured in years.

The broader AI drug design context

Radical Numerics is entering a field that has already seen commercial movement. Insilico Medicine received FDA approval for an AI-designed drug molecule to enter Phase II trials in 2023. Recursion Pharmaceuticals, Isomorphic Labs (a DeepMind spinout), and Absci are all using AI in different parts of the drug discovery pipeline. What sets Radical Numerics apart is the claim of end-to-end AI design of a biological agent — not a small molecule, but a living virus — administered to a human patient.

Bacteriophages are more structurally complex than small molecules and pose different safety considerations: they can evolve, replicate, and potentially interact with the human microbiome in ways that require different monitoring frameworks than traditional drugs.

What to watch

Peer review results are the next critical milestone. If Radical Numerics publishes data showing Omnii-1-designed phages are effective against antibiotic-resistant pathogens, the FDA pathway discussion will accelerate quickly. Watch for preprint submissions to bioRxiv or medRxiv, and for follow-up statements from the treating institution about the patient's outcome.

Source: GTRT